Dr Li Er Loo, MD | |
701 Dellwood St S, Cambridge, MN 55008-1920 | |
(763) 689-7700 | |
Not Available |
Full Name | Dr Li Er Loo |
---|---|
Gender | Female |
Speciality | Obstetrics/gynecology |
Experience | 19 Years |
Location | 701 Dellwood St S, Cambridge, Minnesota |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164716692 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 108637 (Minnesota) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Cambridge Medical Center | Cambridge, MN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Allina Health System | 4587573613 | 3071 |
News Archive
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming."
This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV infection, said AVAC Executive Director Mitchell Warren.
Scientists from Scientific and Educational Center & Smart Materials and Biomedical Applications under the leadership of Kateryna Levada together with colleagues from Center for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University conducted a joint interdisciplinary study on the development of a new method for treating leukemia using nanomaterials.
In 2010, the US National Comprehensive Cancer Network guidelines suggested that patients with stable and low-risk prostate cancers could be managed with active surveillance or watchful waiting (AS/WW). AS/WW was considered to be a safe and effective alternative to aggressive surgery to remove the prostate and radiation therapy.
› Verified 7 days ago
Entity Name | Allina Health System |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming."
This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV infection, said AVAC Executive Director Mitchell Warren.
Scientists from Scientific and Educational Center & Smart Materials and Biomedical Applications under the leadership of Kateryna Levada together with colleagues from Center for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University conducted a joint interdisciplinary study on the development of a new method for treating leukemia using nanomaterials.
In 2010, the US National Comprehensive Cancer Network guidelines suggested that patients with stable and low-risk prostate cancers could be managed with active surveillance or watchful waiting (AS/WW). AS/WW was considered to be a safe and effective alternative to aggressive surgery to remove the prostate and radiation therapy.
› Verified 7 days ago
Entity Name | Allina Health System |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming."
This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV infection, said AVAC Executive Director Mitchell Warren.
Scientists from Scientific and Educational Center & Smart Materials and Biomedical Applications under the leadership of Kateryna Levada together with colleagues from Center for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University conducted a joint interdisciplinary study on the development of a new method for treating leukemia using nanomaterials.
In 2010, the US National Comprehensive Cancer Network guidelines suggested that patients with stable and low-risk prostate cancers could be managed with active surveillance or watchful waiting (AS/WW). AS/WW was considered to be a safe and effective alternative to aggressive surgery to remove the prostate and radiation therapy.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Li Er Loo, MD 2925 Chicago Ave, Minneapolis, MN 55407-1321 Ph: (612) 262-5000 | Dr Li Er Loo, MD 701 Dellwood St S, Cambridge, MN 55008-1920 Ph: (763) 689-7700 |
News Archive
Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.
A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming."
This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV infection, said AVAC Executive Director Mitchell Warren.
Scientists from Scientific and Educational Center & Smart Materials and Biomedical Applications under the leadership of Kateryna Levada together with colleagues from Center for Immunology and Cellular Biotechnology of the Immanuel Kant Baltic Federal University conducted a joint interdisciplinary study on the development of a new method for treating leukemia using nanomaterials.
In 2010, the US National Comprehensive Cancer Network guidelines suggested that patients with stable and low-risk prostate cancers could be managed with active surveillance or watchful waiting (AS/WW). AS/WW was considered to be a safe and effective alternative to aggressive surgery to remove the prostate and radiation therapy.
› Verified 7 days ago
Gail M Lundeen, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 701 Dellwood St S, Cambridge, MN 55008 Phone: 763-689-7700 Fax: 763-689-7941 | |
Dr. Kristina Brittany Mccaughtry, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 701 Dellwood St S, Cambridge, MN 55008 Phone: 763-689-7700 | |
David E. Hovinen, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 701 Dellwood St S, Cambridge, MN 55008 Phone: 763-689-7700 Fax: 763-689-7941 |